文献速递淋巴瘤

利妥昔单抗时代滤泡性淋巴瘤患者继发性血液系统恶性肿瘤风险:1028例分析

Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.
PubMed 文献 · Br J Haematol · 2019-07-03

Follicular lymphoma (FL) is the most common indolent lymphoma. Currently there are many comparable treatment options available for FL. When selecting the most optimal therapy it is important to consider possible late effects of the treatment as well as survival.…

核心结论

  • 利妥昔单抗时代滤泡性淋巴瘤患者一线治疗后SHM风险低,但多线治疗会增加SHM风险。

临床怎么用

  • 治疗策略应尽可能通过一线治疗获得长期缓解,从而推迟SHM额外风险。

局限性

  • 原文自述为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) is the most common indolent lymphoma. Currently there are many comparable treatment options available for FL. When selecting the most optimal therapy it is important to consider possible late effects of the treatment as well as survival. Secondary haematological malignancy (SHM) is a severe late effect of treatments, but the incidence of SHMs is still largely unknown. The goal of the present study was to determine the incidence of SHMs and how therapeutic decisions interfere with this risk. The study included 1028 FL patients with a median follow-up time of 5·6 years. The 5-year risk of SHM was 1·1% and the risk was associated with multiple lines of treatment (P = 0·016). The 5-year risk of SHM was 0·5% after the first-line treatment and 1·6% after the second-line. The standardized incidence ratio (SIR) was 6·2 (95% confidence interval 3·4-10·5) for SHM overall. This retrospective study found that the risk of SHM was low after first-line treatment in FL patients from the rituximab era. However, the risk of SHM increases with multiple lines of treatment. Therapeutic approaches should aim to achieve as long a remission as possible with first-line treatment, thereby postponing the added risk of SHM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Prusila REI, Sorigue M, Jauhiainen J, et al. Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. Br J Haematol. 2019. PMID: 31267514. doi:10.1111/bjh.16090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。